TY  - JOUR
AU  - Onieva, Juan Luis
AU  - Xiao, Qingyang
AU  - Berciano-Guerrero, Miguel-Angel
AU  - Laborda-Illanes, Aurora
AU  - de-Andrea, Carlos
AU  - Chaves, Patricia
AU  - Piñeiro, Pilar
AU  - Garrido-Aranda, Alicia
AU  - Gallego, Elena
AU  - Sojo, Belen
AU  - Galvez, Laura
AU  - Chica-Parrado, Rosario
AU  - Prieto, Daniel
AU  - Perez-Ruiz, Elisabeth
AU  - Farngren, Angela
AU  - Lozano, Maria Jose
AU  - Alvarez, Martina
AU  - Jimenez, Pedro
AU  - Sanchez-Muñoz, Alfonso
AU  - Oliver, Javier
AU  - Cobo, Manuel
AU  - Alba, Emilio
AU  - Barragan, Isabel
PY  - 2022
DO  - 10.3390/ijms23169124
UR  - http://hdl.handle.net/10668/21188
T2  - International journal of molecular sciences
AB  - Resistance to Immune Checkpoint Blockade (ICB) constitutes the current limiting factor for the optimal implementation of this novel therapy, which otherwise demonstrates durable responses with acceptable toxicity scores. This limitation is exacerbated...
LA  - en
PB  - MDPI
KW  - Biomarkers
KW  - Immunotherapy
KW  - Melanoma
KW  - Biomarkers, Tumor
KW  - Humans
KW  - Immune Checkpoint Inhibitors
KW  - Immunotherapy
KW  - Melanoma
KW  - Nivolumab
KW  - Plasma Cells
KW  - Programmed Cell Death 1 Receptor
TI  - High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade.
TY  - research article
VL  - 23
ER  -